Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy

AIDS

Volumn 21, Issue 18, 2007, Pages 2537-2539

  Melby, Thomas E ^a   DeSpirito, Michael ^a   DeMasi, Ralph A ^a   Heilek, Gabrielle ^b   Thommes, James A ^c   Greenberg, Michael L ^a   Graham, Neil ^a  

^a Trimeris Inc   (United States)

^b Roche   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENFUVIRTIDE;

ANALYSIS OF COVARIANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CELL ACTIVATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VIVO GENE TRANSFER; MAJOR CLINICAL STUDY; PATHOGENICITY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; VIRUS INFECTION; VIRUS MUTATION;

CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; PEPTIDE FRAGMENTS; RETROSPECTIVE STUDIES;

EID: 36348936125     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282f12362     Document Type: Article

References (16)

1. Reeves JD, Lee FH, Miamidian JL, Jabara CB, Juntilla MM, Doms RW. Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J Virol 2005; 79:4991-4999.
2. Lu J, Sista P, Giguel F, Greenberg M, Kuritzkes DR. Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J Virol 2004; 78:4628-4637.
3. Marconi V, Bonhoeffer S, Paredes R, Lu J, Hoh R, Martin J, et al. In vivo fitness of enfuvirtide resistant HIV-1 estimated by allele-specific PCR during partial treatment interruption and pulse intensification. In: 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA; 5-8 February 2006. Abstract 629.
4. Pérez-Alvarez L, Carmona R, Ocampo A, Asorey A, Miralles C, Pérez de Castro S, et al. Long-term monitoring of genotypic and phenotypic resistance to T20 in treated patients infected with HIV-1. J Med Virol 2006; 78:141-147.
5. Poveda E, Rodes B, Labernardiere JL, Benito JM, Toro C, Gonzalez-Lahoz J, et al. Evolution of genotypic and phenotypic resistance to enfuvirtide in HIVinfected patients experiencing prolonged virologic failure. J Med Virol 2004; 74:21-28.
6. Aquaro S, D'Arrigo R, Svicher V, Di Perri G, Lo Caputo S, Visco-Comandini U, et al. Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. J Antimicrob Chemother 2006; 58:714-722.
7. Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348:2186-2195.
8. Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348:2175-2185.
9. Nelson M, Arasteh K, Clotet B, Cooper DA, Henry K, Katlama C, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005; 40:404-412.
10. Melby T, Sista P, Demasi R, Kirkland T, Roberts N, Salgo M, et al. Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. AIDS Res Hum Retroviruses 2006; 22:375-385.
11. Etemad-Moghadam B, Rhone D, Steenbeke T, Sun Y, Manola J, Gelman R, et al. Membrane-fusing capacity of the human immunodeficiency virus envelope proteins determines the efficiency of CD4R T-cell depletion in macaques infected by a simian-human immunodeficiency virus. J Virol 2001; 75: 5646-5655.
12. Karlsson GB, Halloran M, Schenten D, Lee J, Racz P, Tenner-Racz K, et al. The envelope glycoprotein ectodomains determine the efficiency of CD4R T lymphocyte depletion in simian- human immunodeficiency virus-infected macaques. J Exp Med 1998; 188:1159-1171.
13. Si Z, Gorry P, Babcock G, Owens CM, Cayabyab M, Phan N, Sodroski J. Envelope glycoprotein determinants of increased entry in a pathogenic simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) passaged in monkeys. AIDS Res Hum Retroviruses 2004; 20:163-173.
14. Garg H, Blumenthal R. HIV gp41-induced apoptosis is mediated by caspase-3-dependent mitochondrial depolarization, which is inhibited by HIV protease inhibitor nelfinavir. J Leukoc Biol 2006; 79:351-362.
15. Meissner EG, Zhang L, Jiang S, Su L. Fusion-induced apoptosis contributes to thymocyte depletion by a pathogenic human immunodeficiency virus type 1 envelope in the human thymus. J Virol 2006; 80:11019-11030.
16. Barretina J, Blanco J, Armand-Ugon M, Gutierrez A, Clotet B, Este JA. Anti-HIV-1 activity of enfuvirtide (T-20) by inhibition of bystander cell death. Antivir Ther 2003; 8:155-161.